The Equilibrium of Tumor Suppression: DUBs As Active Regulators of PTEN

Authors

Audrey Christine
Mi Kyung Park
Su Jung Song
Min Sup Song

Publication Date

11-1-2022

Journal

Experimental & Molecular Medicine

Abstract

PTEN is among the most commonly lost or mutated tumor suppressor genes in human cancer. PTEN, a bona fide lipid phosphatase that antagonizes the highly oncogenic PI3K-AKT-mTOR pathway, is considered a major dose-dependent tumor suppressor. Although PTEN function can be compromised by genetic mutations in inherited syndromes and cancers, posttranslational modifications of PTEN may also play key roles in the dynamic regulation of its function. Notably, deregulated ubiquitination and deubiquitination lead to detrimental impacts on PTEN levels and subcellular partitioning, promoting tumorigenesis. While PTEN can be targeted by HECT-type E3 ubiquitin ligases for nuclear import and proteasomal degradation, studies have shown that several deubiquitinating enzymes, including HAUSP/USP7, USP10, USP11, USP13, OTUD3 and Ataxin-3, can remove ubiquitin from ubiquitinated PTEN in cancer-specific contexts and thus reverse ubiquitination-mediated PTEN regulation. Researchers continue to reveal the precise molecular mechanisms by which cancer-specific deubiquitinases of PTEN regulate its roles in the pathobiology of cancer, and new methods of pharmacologically for modulating PTEN deubiquitinases are critical areas of investigation for cancer treatment and prevention. Here, we assess the mechanisms and functions of deubiquitination as a recently appreciated mode of PTEN regulation and review the link between deubiquitinases and PTEN reactivation and its implications for therapeutic strategies.

Keywords

Humans, Phosphatidylinositol 3-Kinases, Ubiquitination, Ubiquitin, Carcinogenesis, Neoplasms, Deubiquitinating Enzymes, Thiolester Hydrolases, Ubiquitin Thiolesterase, Ubiquitin-Specific Peptidase 7, PTEN Phosphohydrolase

Comments

PMID: 36385557